In the treatment of DN, emodin effectively ameliorates p38 overactivation via activation of PPARγ (Liu et al., 2009), thereby inhibiting renal mesangial cells’ hypocontractility under a high glucose environment. Here, MAPK14 is linked to liver dysplastic nodule.